Several groups have shown that immunosuppression (IS) can be successfully discontinued in a substantial proportion of liver transplant recipients (1). Although transplant tolerance induction in preclinical models is possible and has been studied extensively, understanding of mechanisms and processes leading to so-called operational tolerance (OT) following solid organ transplantation in the clinical setting remains elusive. To reveal factors driving the development of OT and to make weaning from IS drugs safer and less of a trial-and-error process, immune markers and biomarkers have been identified that, in a retrospective analysis, distinguished between successfully weaned tolerant and nontolerant patients (2). The work performed by Sanchez-Fueyo and colleagues revealed that analysis of immune markers in samples collected from the graft tissue itself is more accurate and leads to much higher specificity and sensitivity when distinguishing tolerant and nontolerant liver transplant patients (3).Still lacking in the field are (i) prospective clinical trials in which IS withdrawal is initiated based on the biomarker results and (ii) better understanding of immunological and local processes within the transplanted organ that are induced or operational on IS weaning until reaching a stable stage of tolerance. Biomarker-driven stratification studies are under discussion and have been initiated but require huge financial resources, and the results will not be available for a few years.Local immune processes preceding successful tolerance induction have been investigated almost exclusively in preclinical models, which hardly resemble the clinical situation of IS weaning after long-term use. From those results, it is generally accepted that quantity and quality of local regulatory mechanisms, such as the presence of
Foxp3+ regulatory T cells, determine transplant outcome; however, immune histological investigations on protocol biopsies, collected during or after IS weaning, are rare and show partly conflicting results. More findings from patients enrolled into IS weaning trials are urgently needed.In this issue of the American Journal of Transplantation, Taubert et al (4) have engaged this matter and studied the sequence and phenotype of infiltrating leukocytes following IS withdrawal in patients with OT (5). Apart from quantifying the changes of total portal tract infiltrate, Taubert et al concentrated on the balance of Foxp3 + regulatory and Foxp3À conventional T cells. Immune histology was accompanied by intragraft gene expression analysis. The samples were obtained from patients enrolled into a multicenter clinical trial in which IS was gradually withdrawn over a period of 6-9 months and followed for 60 additional months. In this multicenter trial, weaning was successful in 41 of 102 enrolled patients, from whom 24 were selected for the present investigation based on sample availability at 1 and/or 3 years after weaning. Interestingly, the authors detected an expansion of portal tract infiltration at both time points...